Skip to main content

Table 2 Treatment related characteristics associated with non-cure after anti-tuberculosis treatment in patients diagnosed in 30 remote and poor counties in Shaanxi province, China

From: Factors associated with low cure rate of tuberculosis in remote poor areas of Shaanxi Province, China: a case control study

Treatment characteristic n(%) Treatment result OR 95% CI p-value
   Uncured (%) Cured (%)    
Co-morbidity       < 0.01
No 562 (93.0) 95 (16.9) 467 (83.1) 1   
Yes 42 (7.0) 22 (52.4) 20 (47.6) 5.41 2.84-10.30  
Fever       0.04
No 426 (66.7) 99(23.9) 327 (76.1) 1   
Yes 213 (33.3) 34 (16.0) 179 (84.0) 1.59 1.04-2.45  
Loss of appetite       < 0.01
No 497 (77.8) 92 (18.5) 405 (81.5)    
Yes 142 (22.2) 41 (28.9) 101 (71.1) 1.79 1.17-2.74  
Institute where TB was diagnosed       0.01
CDC 142 (22.2) 60 (17.1) 290 (82.9) 1   
Other 497 (77.8) 73 (25.3) 216 (74.7) 1.63 1.11-2.40  
DOT supervisor       < 0.01
No supervisor 169 (26.4) 48 (28.4) 121 (71.6) 1   
Family 367 (57.4) 73 (19.9) 294 (80.1) 0.63 0.41-0.95  
Doctor 103 (16.1) 12 (11.7) 91 (88.3) 0.33 0.17-0.66  
Number of times forgotten to take drugs       < 0.01
none 541 (84.7) 104 (19.2) 437 (80.8) 1   
≤9 times 76 (11.9) 18 (23.7) 58 (76.3) 1.30 0.74-2.31  
>9 times 22 (3.4) 11 (50.0) 11 (50.0) 4.20 1.77-9.96  
Maximum number of subsequently missed doses       0.01
None 542 (84.8) 105 (19.4) 437 (80.6) 1   
≤ 3 times 64 (10.0) 14 (21.9) 50 (78.1) 1.17 0.62-2.19  
>3 times 33 (5.2) 14 (42.4) 19 (57.6) 3.07 1.49-6.32  
Interruption of treament       < 0.01
No 591 (92.5) 102 (17.3) 489 (82.7) 1   
Yes 48 (7.5) 31 (64.6) 17 (35.4) 8.74 4.66-16.40  
Severity of side effects*       < 0.01
None 361 (56.5) 66 (18.3) 295 (81.7) 1   
Severe 54 (8.5) 27 (50.0) 27 (50.0) 4.47 2.46-8.12  
Medium 41 (6.4) 14 (34.1) 27 (65.9) 2.32 1.15-4.66  
Light 183 (28.6) 26 (14.2) 157 (85.8) 0.74 0.45-1.21  
Sputum re-examination**       < 0.01
Regular 442 (69.2) 57 (12.9) 385 (87.1) 1   
Irregular 155 (24.3) 59 (38.1) 96 (61.9) 4.15 2.71-6.36  
None 42 (6.6) 17 (40.5) 25 (59.5) 4.59 2.34-9.03  
  1. * The severity of side effects is based on the patient's opinion.
  2. ** Regular sputum re-examination: New smear positive cases performing sputum re-examination at the end of the 2nd, 5th and 6th month of the therapy, according to the guidelines.